Skip to main content

Table 5 Annual antipsychotic medication costs among patients with schizophrenia or schizoaffective disorder

From: Can multisite clinical trial results change clinical practice? Use of long-acting injectable risperidone nationally in the Veterans Health Administration

Year

All antipsychotics

LAI risperidone

All LAI SGAs

LAI paliperidone

LAI FGAs

SGA oral

FGA oral

LAI SGA expenditures as % of total antipsychotic expenditures per Veteran

2007

$122,170,267

$12,914,274^

$12,914,274^

$0

$371,238

$76,078,149

$32,806,605

10.6^

2008

$128,140,495

$15,085,187^

$15,085,187^,#

$0

$348,750

$82,396,607

$30,309,950

11.8^

2009

$115,066,407

$16,832,583

$16,881,109^

$48,526^

$358,936

$86,271,426

$11,554,935

14.7^,#

2010

$116,571,834

$16,878,621

18,142,921^,#

$1,263,172^,#

$370,713

$91,405,234

$6,652,966

15.6^,#

2011*

$117,202,917

$16,062,864

$20,802,052

$4,737,495

$805,706

$90,968,967

$4,626,193

17.8

2012

$96,742,862

$14,562,180

$22,761,616^

$8,192,594^

$1,017,493

$68,812,359

$4,151,395

23.5^

2013

$76,508,388

$12,757,391

$23,476,864^

$10,544,810^

$846,056

$48,876,894

$3,308,575

30.7^,#

2014

$70,692,177

$12,378,899

$26,402,932^,#

$13,341,523^,#

$919,701

$40,500,060

$2,869,484

37.4^

2015

$73,982,381

$11,135,327^

$30,164,815^,#

$17,156,228^

$869,519

$40,245,255

$2,702,792

40.8^,#

Change

($48,187,886)

($1,778,947)

$17,250,541

$17,156,228

$498,281

($35,832,894)

($30,103,814)

30.2%

Percent change

 − 39.4%

 − 13.8%

133.6%

–-

134.2%

 − 47.1%

 − 91.8%

285.7%

  1. *Used as the reference year to define pre- and post-publication of a cooperative study (CSP#555)
  2. ^Statistically significant difference as compared to the reference year
  3. #Statistically significant difference when compared to the previous year (excluding comparisons with the reference year)